Ventajas

Ofrece varias ventajas potenciales sobre los tratamientos con fármacos sintéticos:

1. No causa efectos secundarios.

2. No altera los niveles de Antígeno Prostático Específico (PSA), por lo que no enmascara el diagnóstico de cáncer prostático.

3. La mejoría de los síntomas aparece en tan solo 4 a 6 semanas de tratamiento en la mayoría de los pacientes, a diferencia del finasteride, cuyos efectos se observan luego de tres o más meses.

4. Disminuye el tamaño de la próstata, a diferencia de los bloqueadores adrenérgicos.

5. No causa impotencia, por el contrario, puede mejorar el desempeño sexual.

6. Tiene propiedades antisépticas, por lo que mejora las infecciones que a menudo acompañan las enfermedades prostáticas.

Una revisión de 18 estudios clínicos que incluyeron a 2.939 hombres, durante 48 semanas, demostró la efectividad de Saw Palmetto en la disminución de los síntomas urinarios y del tamaño prostático en 66% de los pacientes tratados, en 2 a 4 semanas, con efectos secundarios leves e infrecuentes.

La dosis es de 150 mg dos veces por día. También se pueden ingerir 2 cápsulas una sola vez por día.

Nota: cada cápsula de Adaptógenos contiene 150 mg, a diferencia de otras marcas, que solo contienen 80 mg.

Saw Palmetto puede considerarse una planta sin efectos tóxicos. En muy pocos casos puede presentarse molestias gastrointestinales leves. No se conocen interacciones farmacológicas. No se ha determinado su seguridad en pacientes con disfunción hepática o renal severas.

1. En vista de la alta incidencia de hiperplasia prostática benigna y maligna, y de la ausencia de efectos secundarios de esta planta, todo hombre mayor de 50 años debería recibir Saw Palmetto diariamente, incluso en caso que no presente síntomas urinarios, a título preventivo, con la finalidad de evitar la aparición de la hiperplasia benigna y el cáncer de próstata.

2. Hiperplasia prostática Benigna o Maligna.

1. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001 Dec;58(6):960-4

2. Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 2001 Aug;67(6):489-500

3. Marks LS, Hess DL, Dorey FJ, Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001 May;57(5):999-1005

4. Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, Hirano K. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001 Apr;47(1):59-65

5. Wilt TJ, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 2000 Dec;3(4A):459-72

6. Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K, Hiran K. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol Pharm Bull 2001 Feb;24(2):188-90

7. Marks LS, Partin AW, Epstein JI. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000 May;163(5):1451-6

8. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 2000 May;163(5):1408-12

9. Vacherot F, Azzouz M, Gil-Diez-De-Medina S. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens in benign prostatic hyperplasia. Prostate 2000 Nov 1;45(3):259-66

10. Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens on the prostate. J Urol 2000 Sep;164(3 Pt 1):876-81

11. Stepanov VN, Siniakova LA, Sarrazin B, Raynaud JP. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Adv Ther 1999 Sep-Oct;16(5):231-41

12. Wilt T, Ishani A, Stark G, MacDonald R, Mulrow C, Lau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000;(2):CD001423

13. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000 Apr;55(4):533-9

14. McPartland JM, Pruitt PL. Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study. J Am Osteopath Assoc 2000 Feb;100(2):89-96

15. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999 Sep 1;40(4):232-41

16. Goepel M, Hecker U, Krege S, Rubben H, Michel MC. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 1999 Feb 15;38(3):208-15

17. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998 Nov 11;280(18):1604-9

18. Di Silverio F, Monti S, Sciarra A, Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998 Oct 1;37(2):77-83

19. Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998 Jun;51(6):1003-7

20. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33(3):340-7

21. Plosker GL, Brogden RN. Serenoa repens. A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996 Nov;9(5):379-95

22. Ravenna L, Di Silverio F, Russo MA. Effects of the lipidosterolic extract of Serenoa repens on human prostatic cell lines. Prostate 1996 Oct;29(4):219-30

23. Volpe MA, Cabelin M, Te AE, et al. A prospective trial using saw palmetto versus finasteride in the treatment of chronic nonbacterial prostatitis (CP). Presented at: American Urological Association 2001 Annual Meeting; June 2–7, 2001; Anaheim, Calif.

24. Emili E, Lo Cigno M, Petrone U. Clinical trial of a new drug for treating hypertrophy of the prostate Serenoa repens. Urologia. 1983;50:1042–1048.

25. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol. 1984;18:461–462.

26. Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomology caused by prostatic adenoma using an extract of Serenoa repens. Double-blind clinical study vs. placebo. Minerva Urol Nefrol. 1985;37:87–91.

27. Boccafoschi C, Annoscia S. Comparison of Serenoa repens extract with placebo by controlled clinical trial in patients with prostatic adenomatosis [in Italian]. Urologia. 1983;50:1257–1268.

28. Smith HR, Memon A, Smart CJ, et al. The value of Serenoa repens in benign prostatic hypertrophy. Br J Urol. 1986;58:36–40.

29. Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of ® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest. 1995;9:291–297.

30. Mattei FM, Capone M, Acconcia A. Serenoa repens extract in the medical treatment of benign prostatic hypertrophy [in Italian]. Urologia. 1988;55:547–552.

31. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29:231–240.

32. Debruyne F. Phytotherapy (LSESR) vs an alpha-blocker for treatment of lower urinary tract symptoms secondary to benign prostate enlargement: a randomized comparative study. Presented at: American Urological Association 2001 Annual Meeting; June 2–7, 2001; Anaheim, Calif.

33. Braeckman J, Bruhwyler J, Vandekerckhove K, et al. Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytother Res. 1997;11:558–563.

34. Plosker GL, Brogden RN. Serenoa repens. A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379–395.

35. Plosker GL, Brogden RN. Serenoa repens. A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379–395.

36. Bach D, Schmitt M, Ebeling L. Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH). Phytomedicine. 1996/97;3:309–313.